TAZ and YAP are frequently activated oncoproteins in sarcomas

Oncotarget

Volumn 7, Issue 21, 2016, Pages 30094-30108

  Fullenkamp, Colleen A ^a   Hall, Sarah L ^a   Jaber, Omar I ^a   Pakalniskis, Brittany L ^a   Savage, Erica C ^a   Savage, Johanna M ^a   Ofori Amanfo, Georgina K ^a   Lambertz, Allyn M ^a   Ivins, Stephanie D ^a   Stipp, Christopher S ^b   Miller, Benjamin J ^a   Milhem, Mohammed M ^a   Tanas, Munir R ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Hippo pathway; Pathology Section; Sarcoma; TAZ; WWTR1; YAP

Indexed keywords

ONCOPROTEIN; ONCOPROTEIN TAZ; ONCOPROTEIN YAP; UNCLASSIFIED DRUG; VERTEPORFIN; ANTINEOPLASTIC AGENT; CONNECTIVE TISSUE GROWTH FACTOR; CTGF PROTEIN, HUMAN; DNA BINDING PROTEIN; MUSCLE PROTEIN; PHOSPHOPROTEIN; PORPHYRIN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; TEAD4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; WWTR1 PROTEIN, HUMAN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHONDROSARCOMA; COLONY FORMATION; CONTROLLED STUDY; GENE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; TUMOR GROWTH; WWTR1 GENE; YAP1 GENE; CELL NUCLEUS; DISEASE EXACERBATION; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSCLE PROTEINS; NEOPLASM GRADING; ONCOGENE PROTEINS; PHOSPHOPROTEINS; PORPHYRINS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SARCOMA; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84971542060     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8979     Document Type: Article

References (47)

1. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130:1120-1133
2. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC and Guan KL. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & development. 2007; 21:2747-2761
3. Harvey KF, Pfleger CM and Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003; 114:457-467
4. Pantalacci S, Tapon N and Leopold P. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nature cell biology. 2003; 5:921-927
5. Udan RS, Kango-Singh M, Nolo R, Tao C and Halder G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nature cell biology. 2003; 5:914-920
6. Wu S, Huang J, Dong J and Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003; 114:445-456
7. Justice RW, Zilian O, Woods DF, Noll M and Bryant PJ. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes & development. 1995; 9:534-546
8. Xu T, Wang W, Zhang S, Stewart RA and Yu W. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development (Cambridge, England). 1995; 121:1053-1063
9. Lai ZC, Wei X, Shimizu T, Ramos E, Rohrbaugh M, Nikolaidis N, Ho LL and Li Y. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell. 2005; 120:675-685
10. Harvey KF, Zhang X and Thomas DM. The Hippo pathway and human cancer. Nature reviews Cancer. 2013; 13:246-257
11. Mo JS, Park HW and Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO reports. 2014; 15:642-656
12. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q and Hong W. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer research. 2008; 68:2592-2598
13. Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W and Zhu Q. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PloS one. 2013; 8:e65539
14. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S and Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006; 125:1253-1267
15. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS and Yang X. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 2011; 30:2181-2186
16. Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, Wellstein A, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Science signaling. 2014; 7:ra42
17. de Cristofaro T, Di Palma T, Ferraro A, Corrado A, Lucci V, Franco R, Fusco A and Zannini M. TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. European journal of cancer (Oxford, England: 1990). 2011; 47:926-933
18. Errani C, Zhang L, Sung YS, Hajdu M, Singer S, Maki RG, Healey JH and Antonescu CR. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes, chromosomes & cancer. 2011; 50:644-653
19. Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, Hanwright PJ, Flanagan J, Luo Y, Fenwick K, Natrajan R, Mitsopoulos C, Zvelebil M, Hoch BL, Weiss SW, Debiec-Rychter M, Sciot R, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Science translational medicine. 2011; 3:98ra82
20. Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, Weinreb I, Rubin MA, Hameed M and Fletcher CD. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes, chromosomes & cancer. 2013; 52:775-784
21. Tanas MR, Ma S, Jadaan FO, Ng CK, Weigelt B, Reis-Filho JS and Rubin BP. Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein. Oncogene. 2016; 35:929-38
22. St John MA, Tao W, Fei X, Fukumoto R, Carcangiu ML, Brownstein DG, Parlow AF, McGrath J and Xu T. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nature genetics. 1999; 21:182-186
23. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N and Yaffe MB. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science (New York, NY). 2005; 309:1074-1078
24. Tremblay AM, Missiaglia E, Galli GG, Hettmer S, Urcia R, Carrara M, Judson RN, Thway K, Nadal G, Selfe JL, Murray G, Calogero RA, De Bari C, Zammit PS, Delorenzi M, Wagers AJ, et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer cell. 2014; 26:273-287
25. Crose LE, Galindo KA, Kephart JG, Chen C, Fitamant J, Bardeesy N, Bentley RC, Galindo RL, Chi JT and Linardic CM. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. The Journal of clinical investigation. 2014; 124:285-296
26. Eisinger-Mathason TS, Mucaj V, Biju KM, Nakazawa MS, Gohil M, Cash TP, Yoon SS, Skuli N, Park KM, Gerecht S and Simon MC. Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112:E3402-3411
27. C.D.M. Fletcher JAB, P.C.W. Hogendoorn, F. Mertens. (2013). Pathology and Genetics of Tumours of Soft Tissue and Bone. (Lyon, France: IARC Press)
28. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC and Yaffe MB. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. The EMBO journal. 2000; 19:6778-6791
29. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S and Piccolo S. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011; 147:759-772
30. Coindre JM. (2013). Grading and staging of sarcomas. In: C.D.M. Fletcher JAB, P.C.W. Hogendoorn, F. Mertens, ed. Pathology and Genetics of Tumours of Soft Tissue and Bone. (Lyon, France: IARC Press), pp. 17-18
31. A.P. Dei Tos FP. (2013). Atypical lipomatous tumor. In: C.D.M. Fletcher JAB, P.C.W. Hogendoorn, F. Mertens, ed. Pathology and Genetics of Tumours of Soft Tissue and Bone. (Lyon, France: IARC Press), pp. 33-36
32. A.P. Dei Tos AM-E, F. Pedeutour, S. Rossi. (2013). Dedifferentiated liposarcoma. In: C.D.M. Fletcher JAB, P.C.W. Hogendoorn, F. Mertens, ed. Pathology and Genetics of Tumours of Soft Tissue and Bone. (Lyon, France: IARC Press), pp. 37-38
33. P.C.W. Hogendoorn JVMGB, G.P. Nielsen. (2013). Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma. In: C.D.M. Fletcher JAB, P.C.W. Hogendoorn, F. Mertens, ed. Pathology and Genetics of Tumours of Soft Tissue and Bone. (Lyon, France: IARC Press), pp. 264-268
34. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y and Guan KL. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Molecular and cellular biology. 2008; 28:2426-2436
35. Zhao B, Li L, Tumaneng K, Wang CY and Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes & development. 2010; 24:72-85
36. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li T, Chan SW, Lim CJ, Hong W, Zhao S, Xiong Y, Lei QY and Guan KL. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF(beta)-TrCP E3 ligase. The Journal of biological chemistry. 2010; 285:37159-37169
37. Yagi R, Chen LF, Shigesada K, Murakami Y and Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. The EMBO journal. 1999; 18:2551-2562
38. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C and Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. The Journal of biological chemistry. 2009; 284:14347-14358
39. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY and Guan KL. TEAD transcription factors mediate the function of TAZ in cell growth and epithelialmesenchymal transition. The Journal of biological chemistry. 2009; 284:13355-13362
40. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC and Guan KL. TEAD mediates YAP-dependent gene induction and growth control. Genes & development. 2008; 22:1962-1971
41. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes & development. 2012; 26:1300-1305
42. Hau JC, Erdmann D, Mesrouze Y, Furet P, Fontana P, Zimmermann C, Schmelzle T, Hofmann F and Chene P. The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences. Chembiochem. 2013; 14:1218-1225
43. Tan G, Cao X, Dai Q, Zhang B, Huang J, Xiong S, Zhang Y, Chen W, Yang J and Li H. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional coactivators YAP and TAZ. Oncotarget. 2015; 6:8676-8686. doi:10.18632/oncotarget.3254
44. Feng X, Chen Q and Gutkind JS. Oncotargeting G proteins: The Hippo in the room. Oncotarget. 2014; 5:10997-10999. doi:10.18632/oncotarget.2815
45. Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, Chen Q and Gutkind JS. Hippoindependent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer cell. 2014; 25:831-845
46. Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W, Zhao J, Chen X, Zhang L, Wang CY, Bastian BC, Zhang K, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer cell. 2014; 25:822-830
47. Taccioli C, Sorrentino G, Zannini A, Caroli J, Beneventano D, Anderlucci L, Lolli M, Bicciato S and Del Sal G. MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. Oncotarget. 2015; 6:38854-38865. doi:10.18632/oncotarget.5749